PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8447409-5	1993	L-NAME (3 mg/kg) injected intravenously 15 min before RX 77368 completely prevented the increase in GMBF induced by the TRH analogue, whereas the acid response was not modified.	gmbf	100-104	thyrotropin releasing hormone	Rattus norvegicus	120-123
1560592-4	1992	PYY caused inhibition of baclofen-stimulated gastric acid output and reduction in baclofen-stimulated GMBF in a dose-dependent manner, however PYY didn"t cause inhibition of pentagastrin- and histamine-induced acid output completely.	gmbf	102-106	peptide YY	Rattus norvegicus	0-3
1443154-3	1992	After vasopressin infusion, LDV signal and indexes of hemoglobin (IHb) and oxygen (ISO2) content in the gastric mucosa estimated by RS significantly decreased in parallel with the reduction of gastric mucosal blood flow (GMBF).	gmbf	221-225	arginine vasopressin	Rattus norvegicus	6-17
1345184-6	1992	The drugs given in doses of 10 or 50 micrograms/kg for L-PIA and 1 or 5 micrograms/kg for NECA, dose-dependently inhibited GMBF and potentiated ethanol-induced gastric damage.	gmbf	123-127	ribosomal protein L4	Rattus norvegicus	55-66
1656776-6	1991	Intra-arterial infusion of CGRP (20 pmol/min) close to the stomach produced a marked rise in GMBF and this was completely blocked by hCGRP-(8-37) (500 pmol/min).	gmbf	93-97	calcitonin-related polypeptide alpha	Rattus norvegicus	27-31
1889688-3	1991	CBS treated animals revealed a highly statistically significant increase (P less than 0.0005, upaired t-test) of GMBF in comparison with the placebo treated.	gmbf	113-117	cystathionine beta synthase	Rattus norvegicus	0-3
4059586-9	1985	Neurotensin plus secretin reduced GMBF by 14 (12-27) ml/min but not significantly more than neurotensin at 11 (3-20) ml/min or secretin 18 (2-27) ml/min alone.	gmbf	34-38	neurotensin	Homo sapiens	0-11
1702035-6	1991	Basal GMBF was in the range of 35-50 ml/min/100 g. Infusion of rat alpha-CGRP (15 and 75 pmol/min) significantly increased GMBF in a dose-dependent manner, whereas mean arterial blood pressure was significantly lowered only by the higher dose of CGRP.	gmbf	6-10	calcitonin-related polypeptide alpha	Rattus norvegicus	73-77
1702035-6	1991	Basal GMBF was in the range of 35-50 ml/min/100 g. Infusion of rat alpha-CGRP (15 and 75 pmol/min) significantly increased GMBF in a dose-dependent manner, whereas mean arterial blood pressure was significantly lowered only by the higher dose of CGRP.	gmbf	123-127	calcitonin-related polypeptide alpha	Rattus norvegicus	73-77
1702035-8	1991	Infusion of rat VIP (25 pmol/min) failed to affect GMBF and mean arterial blood pressure, whereas a fivefold higher dose of VIP (125 pmol/min) led to a significant rise of GMBF and to significant hypotension.	gmbf	172-176	vasoactive intestinal peptide	Rattus norvegicus	124-127
1702035-10	1991	CGRP and VIP, however, can be considered as candidate mediators of submucosal nerve endings involved in the neural control of GMBF.	gmbf	126-130	calcitonin-related polypeptide alpha	Rattus norvegicus	0-4
1702035-10	1991	CGRP and VIP, however, can be considered as candidate mediators of submucosal nerve endings involved in the neural control of GMBF.	gmbf	126-130	vasoactive intestinal peptide	Rattus norvegicus	9-12
2872716-4	1986	The ratios between GMBF and secretion (acid and pepsin) were increased during somatostatin infusion, which suggests a relative increase in mucosal blood flow and independent inhibition of gastric secretion.	gmbf	19-23	somatostatin	Canis lupus familiaris	78-90
4059586-9	1985	Neurotensin plus secretin reduced GMBF by 14 (12-27) ml/min but not significantly more than neurotensin at 11 (3-20) ml/min or secretin 18 (2-27) ml/min alone.	gmbf	34-38	secretin	Homo sapiens	17-25
175432-3	1976	With increasing doses of 13-nle-motilin, GMBF increased to 148% of control values; pepsin secretion  - due to augmented pepsin concentration - rose concomitantly.	gmbf	41-45	motilin	Canis lupus familiaris	32-39
19427335-9	2009	all inhibited the GMBF-improving effect of GLP-1.	gmbf	18-22	glucagon	Homo sapiens	43-48
25596156-10	2015	GLP-2 on GMBF.	gmbf	9-13	mast cell protease 10	Rattus norvegicus	0-5
25596156-17	2015	GMBF increased rapidly following 100ng GLP-2 injection and did not fall to the basal levels during 35min.	gmbf	0-4	mast cell protease 10	Rattus norvegicus	39-44
25596156-21	2015	significantly prevented the increase in GMBF due to GLP-2 (100ng; i.c.v.	gmbf	40-44	mast cell protease 10	Rattus norvegicus	52-57
28056423-16	2017	CONCLUSION: Our data show that EPI protects against NAP-induced gastric and intestinal damage by reducing pro-inflammatory cytokines, reducing oxidative stress, and increasing GMBF.	gmbf	176-180	catenin, beta like 1	Rattus norvegicus	52-55
26004410-7	2015	The increase in the GMBF response associated with acid back-diffusion after the TC treatment was also inhibited by the chemical ablation of capsaicin-sensitive afferent neurons, but not capsazepine, a TRPV1 antagonist.	gmbf	20-24	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	201-206
26004410-8	2015	Thus, endogenous PGE2 produced by COX-1 plays a role in the gastric hyperemic response following barrier disruption of the stomach by interacting with capsaicin-sensitive afferent neurons, mainly through EP1 receptors, and facilitating the GMBF response to acid back-diffusion.	gmbf	240-244	cytochrome c oxidase I, mitochondrial	Mus musculus	34-39
23920479-5	2013	RESULTS: The nNOS inhibitor N(5)-[imino(propylamino)methyl]-L-ornithine substantially reduced GMBF during capsaicin application, whereas the endothelial NOS (eNOS) inhibitor N(5)-(1-iminomethyl)-L-ornithine did not affect the effect of capsaicin during the application.	gmbf	94-98	nitric oxide synthase 1	Rattus norvegicus	13-17
17465507-6	2007	In comparison with control group, the GMBF was 0.52 +/- 0.161 mL vs 1.03 +/- 0.255 mL per 100g tissue/min, P < 0.01, the content of motilin in sinus ventriculi and bulbus medullae was 63.04 +/- 7.77 pg/mL vs 72.91 +/- 8.42 pg/mL, P < 0.05 and 50.96 +/- 8.77 pg/mL vs 60.76 +/- 8.05 pg/mL, P < 0.05, but the content of somatostatin in sinus ventriculi and bulbus medullae was 179.85 +/- 43.13 ng/g vs 90.54 +/- 40.42 ng/g, P < 0.01 and 532.86 +/- 122.58 ng/g vs 370.91 +/- 76.29 ng/g, P < 0.05,respectively.	gmbf	38-42	motilin	Rattus norvegicus	135-142
12918118-6	2003	The area of gastric mucosal lesion was reduced by 64.9 % and GMBF was increased by 89.8 % at 8 h. The healing of stress-induced ulcerations was accompanied by increased expression of pS2 (0.51+/-0.14 vs 0.77+/-0.11, P<0.01) and ITF (0.022+/-0.001 vs 0.177+/-0.010, P<0.01).	gmbf	61-65	trefoil factor 1	Rattus norvegicus	183-186
15612669-6	2004	There was a significant positive correlation between the gastric mucosal EF-1 concentration and the UI (r = 0.98, P < 0.01), and a significant negative correlation between the gastric mucosal ET-1 concentration and GMBF (r = -0.89, P < 0.01) and also between the UI and GMBF (r = -0.98, P < 0.01).	gmbf	218-222	endothelin 1	Rattus norvegicus	195-199
15612669-10	2004	The mechanism of action may be associated with a reduction of GMBF induced by ETAR-mediated vasoconstriction.	gmbf	62-66	endothelin receptor type A	Rattus norvegicus	78-82
15369704-6	2004	These findings demonstrate that endothelial PAR-1 and PAR-2, upon activation, dilate the gastric artery via NO and prostanoid formation and also EDHF mechanisms including gap junctions, which would enhance GMBF.	gmbf	206-210	coagulation factor II (thrombin) receptor	Rattus norvegicus	44-49
15369704-6	2004	These findings demonstrate that endothelial PAR-1 and PAR-2, upon activation, dilate the gastric artery via NO and prostanoid formation and also EDHF mechanisms including gap junctions, which would enhance GMBF.	gmbf	206-210	F2R like trypsin receptor 1	Rattus norvegicus	54-59
21166240-3	2003	RESULTS: (1) Arterial infusions of CGRP and G17 (5, 50 and 100 pmol x min(-1)) increased GMBF significantly in dose-dependent manners.	gmbf	89-93	calcitonin-related polypeptide alpha	Rattus norvegicus	35-39
21166240-8	2003	(3) Arterial infusion of NPY (5, 50 and 100 pmol x min(-1)) led to reduction of GMBF significantly in a dose-dependent manner.	gmbf	80-84	neuropeptide Y	Rattus norvegicus	25-28
21166240-11	2003	The increases in GMBF induced by icv microinjection of CGRP or G17 were blocked completely or partially respectively by pretreatments with L-NAME.	gmbf	17-21	calcitonin-related polypeptide alpha	Rattus norvegicus	55-59
12970102-10	2003	Combined administration of apamin and charybdotoxin, but not each of them, specifically abolished the hypotension, increased GMBF and decreased GMVR caused by the PAR-2 agonists.	gmbf	125-129	F2R like trypsin receptor 1	Rattus norvegicus	163-168
12527143-11	2003	CONCLUSION: Somatostatin-induced gastroprotection and restoration of GMBF during ethanol exposure involve mechanisms which are dependent on NO generation.	gmbf	69-73	somatostatin	Rattus norvegicus	12-24
10983857-10	2000	NCX-4016, though absorbed more slowly than ASA, counteracts the injurious effect of aspirin on the gastric mucosa, probably by increasing GMBF mediated by NO.	gmbf	138-142	solute carrier family 8 member A1	Rattus norvegicus	0-3
10705173-7	2000	RESULTS: Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t. CONCLUSION: Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine.	gmbf	150-154	vascular endothelial growth factor A	Homo sapiens	364-368
10705173-7	2000	RESULTS: Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t. CONCLUSION: Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine.	gmbf	150-154	vascular endothelial growth factor A	Homo sapiens	497-501
10705173-7	2000	RESULTS: Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t. CONCLUSION: Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine.	gmbf	150-154	vascular endothelial growth factor A	Homo sapiens	497-501
10705173-7	2000	RESULTS: Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t. CONCLUSION: Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine.	gmbf	150-154	vascular endothelial growth factor A	Homo sapiens	364-368
10705173-7	2000	RESULTS: Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t. CONCLUSION: Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine.	gmbf	150-154	vascular endothelial growth factor A	Homo sapiens	497-501
10705173-7	2000	RESULTS: Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t. CONCLUSION: Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine.	gmbf	150-154	vascular endothelial growth factor A	Homo sapiens	497-501
9458786-5	1998	These findings indicate that vagal efferent activation induced by TRH analog injected intracisternally at a gastric acid secretory dose increases GMBF through atropine-sensitive mechanisms stimulating L-arginine-nitric oxide pathways, whereas H1 receptors and capsaicin-sensitive afferent fibers do not play a role.	gmbf	146-150	thyrotropin releasing hormone	Rattus norvegicus	66-69
9772541-7	1997	CONCLUSION: GMBF was decreased by increased ET, Ang-II and decreased H2, alpha 1 receptor in CBDL, under stress.	gmbf	12-16	angiotensinogen	Rattus norvegicus	48-54
9392832-5	1997	These findings indicate that [4Cl-D-Phe6,Leu17]VIP is an antagonist for exogenous VIP-induced gastric hyperemia and hypotension and that VIP modulates the systemic blood pressure response to IC RX 77368 at 30 ng while not playing a primary role in the increase of GMBF.	gmbf	264-268	vasoactive intestinal peptide	Rattus norvegicus	47-50
9428220-4	1998	The present experiments were performed to elucidate whether CGRP increases GMBF through the activation of KATP channels and whether the channels are involved in the protection by CGRP of gastric mucosa.	gmbf	75-79	calcitonin-related polypeptide alpha	Rattus norvegicus	60-64
9392832-3	1997	The thyrotropin-releasing hormone (TRH) stable analog, RX 77368, injected intracisternally (IC, 30 ng) increased GMBF and blood pressure.	gmbf	113-117	thyrotropin releasing hormone	Rattus norvegicus	4-33
9392832-3	1997	The thyrotropin-releasing hormone (TRH) stable analog, RX 77368, injected intracisternally (IC, 30 ng) increased GMBF and blood pressure.	gmbf	113-117	thyrotropin releasing hormone	Rattus norvegicus	35-38